Mineralys Therapeutics, Inc. Liquidation Value

Mineralys Therapeutics (MLYS) is a pre-revenue clinical-stage biopharmaceutical company with no product sales, no AR, no inventory, and no meaningful PP&E. The liquidation analysis is straightforward: the balance sheet is dominated by liquid financial assets against a minimal liability stack, producing a positive and substantial recovery to equity under a liquidation scenario — an unusual outcome for a clinical-stage biotech, driven entirely by the company's ability to raise and preserve capital ahead of its NDA decision.

As of March 31, 2026, total assets were $652.9M, of which $652.5M was current (99.9% current). The asset base consists of $112.8M cash and cash equivalents (at-par recovery) and $533.3M in held-to-maturity U.S. Treasury bills classified as current investments (maturities between 3 and 12 months, carried at amortized cost of $533.3M vs. fair value of $533.2M — negligible haircut). Prepaid and other current assets of $6.4M receive modest haircut under liquidation. Non-current assets are $0.4M (PP&E net $32K, other assets $360K including $200K deferred offering costs — both round to zero under liquidation).

Total liabilities are $14.7M, entirely current: accounts payable $1.1M and accrued liabilities $13.6M ($4.6M R&D accruals, $2.3M compensation, $6.7M professional fees). No long-term debt, no operating lease obligations, no pension. The Tanabe license carries contingent commercial milestone obligations of up to $155M (first indication) plus $10M (second indication) and tiered royalties of mid-single digits to 10% of net sales — none of these obligations are accrued on the balance sheet because they are contingent on commercial milestones not yet triggered. Under a liquidation scenario the Tanabe License would be terminated per its provisions (90-180 days notice), eliminating royalty exposure, though the contingent milestone payments are not extinguished obligations today.

Liquidation value: applying 100% to cash/equivalents ($112.8M) and T-bills ($533.3M) and minimal haircuts to prepaid ($6.4M at ~50% = $3.2M), less face-value liabilities ($14.7M), produces estimated recovery of approximately $635M — roughly in line with the GAAP book equity of $638.1M. This is consistent with a company that holds essentially no illiquid or intangible assets.

Period-over-period: from December 31, 2025 (GAAP equity $646.7M), equity declined $8.6M due to Q1 2026 net loss of $39.3M offset by $24.2M in equity issuances (ATM proceeds $20.2M net + option exercises $4.1M). Total cash plus investments decreased from $666.6M (Dec 2025: $172.9M cash + $493.7M investments) to $646.1M (Mar 2026: $112.8M cash + $533.3M investments), a $20.5M decline consistent with operating cash burn of $39.5M offset by $24.3M financing and net investment roll. Operating burn rate of ~$39.5M/quarter implies approximately 16 quarters of runway at current rates, though the company's own guidance is at least 12 months. The filing does not separately XBRL-tag the Tanabe commercial milestone obligations or the ATM program's remaining capacity ($187.2M), both discussed in MD&A. G&A expenses tripled year-over-year to $21.0M in Q1 2026 from $6.6M in Q1 2025, reflecting pre-commercial build-out ahead of the December 22, 2026 PDUFA date — a liability-creating operational trajectory not yet reflected on the balance sheet.